Literature DB >> 6538844

Effect of a reversible and selective MAO-A inhibitor (cimoxatone) on diurnal variation in plasma prolactin level in man.

M Strolin Benedetti, A Eschalier, A Lesage, G Dordain, V Rovei, E Zarifian, P Dostert.   

Abstract

Prolactin (PRL) secretion is stimulated by serotonin (5-HT) and inhibited by dopamine (DA). 5-HT is generally recognized as a substrate for type A monoamine oxidase (MAO), whereas DA is considered as a substrate for either A or B, or both forms of MAO, depending on the species and tissues used. The effect of cimoxatone, a reversible, selective MAO-A inhibitor, on diurnal variation in plasma PRL level was investigated in healthy adults after a single 40 mg oral dose, as an indirect approach to investigating whether DA is preferentially a substrate for Type A or B MAO in man. The circadian rhythm in PRL, stress conditions and diet were taken into account in the present study, which was placebo-controlled. There was a slight but significant reduction in circulating PRL in the six subjects, which persisted for at least 9 h after cimoxatone. However, the duration of the decrease in plasma PRL was shorter than the inhibition of MAO-A. The results are not inconsistent with the presence of both forms of MAO in the human hypothalamus and with DA as a substrate for both forms in this region, if it is assumed that the hypothalamic concentrations of the drug during the period 0-9 hours was sufficiently high to inhibit DA deamination by both forms of MAO.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538844     DOI: 10.1007/bf00546712

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  37 in total

1.  Studies on the distinction between uptake inhibition and release of (3H)dopamine in rat brain tissue slices.

Authors:  R E Heikkila; H Orlansky; G Cohen
Journal:  Biochem Pharmacol       Date:  1975-04-15       Impact factor: 5.858

2.  IGPHARM: interactive graphic package for pharmacokinetic analysis.

Authors:  C Gomeni; R Gomeni
Journal:  Comput Biomed Res       Date:  1978-08

3.  Neuropharmacological intervention on the pituitary-hypothalamic relationship.

Authors:  J Tuomisto
Journal:  Ann Clin Res       Date:  1978

4.  Effects of serotonin precursors and melatonin on serum prolactin release in rats.

Authors:  K H Lu; J Meites
Journal:  Endocrinology       Date:  1973-07       Impact factor: 4.736

Review 5.  Hypothalamic dopamine neurons and hypothalamic peptides.

Authors:  T Hökfelt; O Johansson; K Fuxe; R Elde; M Goldstein; D Park; S Efendic; R Luft; H Fraser; S Jeffcoate
Journal:  Adv Biochem Psychopharmacol       Date:  1977

6.  Monoamine-oxidase inhibitors and prolactin secretion.

Authors:  J Mendlewicz; M B Youdim
Journal:  Lancet       Date:  1977-09-03       Impact factor: 79.321

7.  The effect of monoamine oxidase A and B inhibitors on rat serum prolactin.

Authors:  P E Keane; J Menager; M Strolin Benedetti
Journal:  Neuropharmacology       Date:  1981-12       Impact factor: 5.250

8.  Short- and long-term fluctuations in plasma prolactin concentration in normal subjects.

Authors:  H Djursing; C Hagen; J Møller; C Christiansen
Journal:  Acta Endocrinol (Copenh)       Date:  1981-05

9.  The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone.

Authors:  C J Fowler; M S Benedetti
Journal:  J Neurochem       Date:  1983-06       Impact factor: 5.372

10.  Acute prolactin release triggered by feeding.

Authors:  M E Quigley; J F Ropert; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1981-05       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.